With the way cleared for increased use of the fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT) in the United States, the issue of possible public health impacts associated with this additive has gained greater attention. In assessing potential health risks of particulate Mn emitted from the combustion of MMT in gasoline, the U.S. Environmental Protection Agency not only considered the qualitative types of toxic effects associated with inhaled Mn, but conducted extensive exposure-response analyses using various statistical approaches and also estimated population exposure distributions of particulate Mn based on data from an exposure study conducted in California when MMT was used in leaded gasoline. Because of limitations in available data and the need to make several assumptions and extrapolations, the resulting risk characterization had inherent uncertainties that made it impossible to estimate health risks in a definitive or quantitative manner. To support an improved health risk characterization, further investigation is needed in the areas of health effects, emission characterization, and exposure analysis. Environ Health Perspect 1 06(Suppl 1): 191-201 (1998). http.//ehpnet1.niehs.nih.gov/ docs/1998/Suppl-1/191-201Jdavis/abstract.html
Introduction
Methylcyclopentadienyl manganese tricarbonyl (MMT) is an organometallic compound developed by the Ethyl Corporation (Richmond, VA) in the 1950s to increase the octane level of gasoline and thereby enhance the antiknock properties of the fuel. It also was marketed to improve the combustion of fuel oil and turbine fuel (1) . Even before the introduction of MMT into the U.S. fuel supply began in 1976, concerns were raised about its potential public health implications (2) . After passage of the 1977 amendments to the Clean Air Act (CAA) (3), however, the manganese (Mn) additive was legal for use only in leaded gasoline. According to the Ethyl Corporation (4) over 70 million pounds of MMT have been sold for use in U.S. leaded gasoline since 1976. In 1979, while crude oil was in short supply, the U.S. Environmental Protection Agency (U.S. EPA) also allowed MMT to be added to unleaded gasoline for a few months. The limited usage of MMT in leaded gasoline was permitted until lead was phased out of U.S. gasoline at the end of 1995. The Ethyl Corporation has applied to the U.S. EPA several times since 1978 for (919) 541-0245. E-mail: davis.jmichael@epamail.epa.gov Abbreviations used: CAA, Clean Air Act; CNS, central nervous system; F/FA, fuel and fuel additive; IRIS, integrated risk information system; LOAEL, lowest observed adverse effect level; MMT, methylcyclopentadienyl manganese tricarbonyl; NOAEL, no observed adverse effect level; PM, particulate matter (subscript number indicates fiber particle size in pm); PTEAM, particle total exposure assessment methodology; RfC, inhalation reference concentration; RfD, oral reference dose; TEL, tetraethyl lead; TLV, threshold limit value; U.S. EPA, U.S. Environmental Protection Agency; VMT, vehicle miles traveled.
permission to sell MMT 180 days of receipt of the application, the statute provides that the waiver shall be automatically granted. Four waiver petitions submitted by the Ethyl Corporation were denied because of concerns regarding increases in exhaust hydrocarbon emissions resulting from MMT use. During consideration of the third and fourth applications, the U.S. EPA also raised concerns regarding the possible adverse health effects of an increase in airborne Mn resulting from MMT use. Ultimately, in July 1994, the U.S. EPA Administrator denied the Ethyl Corporation's waiver petition specifically because of concerns about risks to public health (5) . In 1995, the Ethyl Corporation successfully challenged the denial of its petition in federal court (6). The court ruled that Section 211 (f)(4) of the CAA (3) provides no basis for U.S. EPA to deny Ethyl's petition on any grounds except whether MMT would cause or contribute to a failure of any emission control device or system.
In May 1994, as mandated in CAA (3) Section 211(b) and (e), the U.S. EPA issued the F/FA rule (7) , which required that F/FA manufacturers provide evidence from existing studies or conduct new tests to address specified health end points (i.e., at a minimum, subchronic inhalation toxicity studies that include reproductive and developmental toxicity, neurotoxicity, and mutagenicity end points). Under the F/FA rule, manufacturers whose products were not chemically similar to F/FAs previously registered by the U.S. EPA could not market their products until specified toxicity and other information was provided to the agency. Although the U.S. EPA maintained that MMT had not been previously registered, the Ethyl Corporation successfully challenged that position as well (8) . Consequently, the Ethyl Corporation has been marketing MMT Unlike lead, the oral route of exposure is considered less of a threat with Mn. Dietary Mn has relatively low toxicity at most exposure levels due in part to a low rate of absorption from the gastrointestinal tract and in part to efficient regulation by homeostatic mechanisms (15) . The Mn oral reference dose (RfD) is 0.14 mg/kg/day for dietary sources. However, for nondietary sources such as water or soil and especially for infants consuming formula prepared with water, a value of 0.05 mg/kg/day is specified by the U.S. EPA (15) . The Mn RfD reflects the fact that Mn is considered a nutritionally essential trace element; it is required for enzymes such as hydrolases, kinases, decarboxylases, and transferases, and for metalloenzymes such as mitochondrial superoxide dismutase, which are important for normal functioning of the central nervous system (CNS) and other systems. However, Mn toxicity to workers exposed by inhalation has been recognized since the early 1800s (16) (24) . The first is a psychiatric aspect that includes disturbances such as excessive weeping and laughing, sleep disturbances, irritability, apathy, and anorexia. The term manganese madness (locura manganica) is sometimes applied to these symptoms of Mn toxicity (25) . A second phase consists of neurologic and neuromuscular signs such as gait disturbances, dysarthria, dumsiness, muscle cramps, intention tremor, and masklike facial expressions. In addition a final stage of Mn intoxication may involve symptoms of irreversible dystonia and hyperflexion of muscles that may not appear until many years after the onset of exposure (25) . Similarities between the later stages of manganism and Parkinson's disease have been noted frequently because of the impairment of fine motor control, lack of facial expression, and apparent involvement of underlying common neuroanatomical and neurochemical factors (26, 27) . However, most clinical neurologists now differentiate, both functionally and neuroanatomically, between the two afflictions of the extrapyramidal tracts (28) .
The precise mechanisms of Mn neurotoxicity are not well understood, but it appears that Mn can affect several different aspects of CNS structure and function.
Postmortem examinations of Mn-exposed humans and experimental studies of Mnexposed laboratory animals indicate that Mn is distributed preferentially to nuclei of the basal ganglia, particularly the caudate, putamen, globus pallidus, subthalamic nucleus, and substantia nigra, and to a lesser extent to other regions of the brain, including the cerebellum and pituitary (29) (30) (31) . Generally the primary sites of neuropathologic changes associated with Mn toxicity in humans and experimental animals are the basal ganglia, particularly the globus pallidus, caudate, and putamen. There is little or no involvement of the substantia nigra (29) (30) (31) (32) (33) . Investigation of the mechanisms of Mn neurotoxicity has focused on the oxidative properties of Mn (especially Mn3+) and its interactions with the dopaminergic system, including biphasic increases and decreases in dopamine levels associated with Mn exposure (34) . The role of nigrostriatal pathways and dopaminergic and y-aminobutyric neurons in Mn neurotoxicity has not been fully established; some evidence suggests that the nigrostriatal pathway itself remains intact, with damage occurring postsynaptically (31, 35) . Mitochondrial uptake and disruption have also been investigated as mechanisms of Mn neurotoxicity (36, 37) .
Other organs and systems are also targets of Mn toxicity. Respiratory effects such as pneumonia, susceptibility to acute infections of the respiratory tract, and cough have been noted in Mn workers (38, 39 
Inhalaton Reference

Concentration for Manganese
The 1993 RfC for Mn (47) was based primarily on a study of Mn-exposed alkaline-battery plant workers in Belgium by Roels et al. (45) . This cross-sectional study evaluated neurobehavioral and other end points in 92 male workers exposed to Mn dioxide (MnO2) dust, compared to a matched control group of 101 male workers without industrial Mn exposure. The geometric mean occupational-lifetime integrated respirable fraction of particulate matter (PM5) (subscript number indicates particle size in pm) dust concentration was 793 pg Mn/m3 x years (range: 40-4,433). The Mn-exposed workers performed significantly worse than matched controls on several measures of neurobehavioral function, particularly tests of eye-hand coordination, hand steadiness, and visual reaction time.
Similar neurobehavioral impairments were also found in an earlier study by Roels et al. (39) of a different occupational population in Belgium exposed to comparable (total dust) concentrations of mixed Mn oxides and salts. In addition, a study of Canadian workers by Mergler et al. (48) indicated that compared to matched controls, performances on tests of rapid alternating hand movements, hand steadiness, and other aspects of fine motor control were significantly worse in workers who had been exposed to even lower concentrations of respirable Mn dust than those measured by Roels et al. (45) (47) .
In deriving an RfC for-Mn, the geometric mean integrated respirable dust concentration (793 pg Mn/m3 x years) from Roels et al. (45) was divided by the average period of worker exposure (5.3 years) to eliminate time (in years) from the time-weighted average, thereby yielding a lowest observed adverse effect level (LOAEL) of 150 pg Mn/m3. Other adjustments made to relate the occupational exposure (e.g., 5 days/lOm3 air breathed per week, day) to lifetime environmental exposure (7 days/20m3 air breathed per day) produced an exposure-adjusted LOAEL of 50 pg Mn/m3. This value was then divided by a total uncertainty factor of 1000 to yield an RfC of 0.05 pg/m3. The total uncertainty factor of 1000 incorporated the following factors: 10 to protect sensitive individuals (e.g., infants, pregnant women, elderly), 10 for using an LOAEL in lieu of a no observed adverse effect level (NOAEL), and a composite factor of 10 for database limitations. The composite factor subsumed three areas of uncertainty: extrapolation from subchronic to chronic exposure, inadequate reproductive and developmental data, and unknown differences in the toxicity of different forms of Mn.
After the U.S. EPA issued the RfC for Mn in 1993 (47), the Ethyl Corporation requested that the U.S. EPA consider alternative approaches to analyzing the data of Roels et al. (45) and including supplementary data provided by Roels (52 (61) .
The only published study that has used a probability-based representative sampling design for evaluating exposure levels of Mn in a general population was the particle total exposure assessment methodology (PTEAM) study (62 
Risk Characterization
To assess health risks, qualitative and quantitative health effects information must be related to available exposure information. From the standpoint of a qualitative hazard identification, the available evidence amply demonstrates that inhaled Mn is toxic to the nervous system, the respiratory system, and the male reproductive system. Although occupational epidemiologic findings of impaired motor function (e.g., reductions in eye-hand coordination, slower hand or finger movements, and less control of fine movement) may be subde and probably not readily evident to clinical physicians, they are nevertheless significant from a public health standpoint when considered as potential population effects.
Quantitative (80, 81) . Note that Parkinson's disease is typically a geriatric disease in which symptoms are seen only when the loss of brain cells that produce dopamine (the loss of which may also be involved in Mn toxicity) reaches 80% or more. If Mn were to contribute to such losses, the effect could be a more severe or earlier onset of declining function in senescence (82, 83) .
Recent epidemiologic studies of occupational cohorts do litde to reduce this concern because of the relatively young populations studied. The oldest worker in the study by Roels much of the clinical literature on manganism refers to a psychiatric component of the illness that often involves striking emotional or mood changes that tend to appear before changes in motor function are evident. Some more recent investigations (94) suggest that aggressive behavior may be associated with Mn exposure (as reflected in the concentration of Mn in hair of prison inmates). However, these reports require substantiation by further studies, and the validity and relevance of hair Mn levels as an indicator of environmental Mn exposure remains to be established.
The exposure assessment was built on the PTEAM study (62) . Given 
Research Directions
On 12 March 1991 the U.S. EPA and the National Institute of Environmental Health Sciences jointly sponsored an international symposium on health and exposure issues related to Mn and MMT, followed by a workshop on 13-15 March, which was attended by more than 100 experts in the fields of exposure and health sciences (95) . The discussions in this workshop provided useful input to U.S. EPA scientists as they developed a program of studies that would provide information needed to support an improved, quantitative assessment of the potential risks to public health associated with MMT (96) . Although the identification of these information needs preceded the reevaluation that figured into the 1994 U.S. EPA denial of the waiver petition by the Ethyl Corporation, the needs have remained largely unchanged since 1991.
Under health effects a major part of the rationale for the program of studies condsidered most needed was the premise that Mn304 was the predominant form of Mn to which human populations would be exposed in conjunction with MMT (85) and noninhalation routes (43, (75) (76) (77) , they appear less likely to show behavioral effects at the same exposure levels (102) . Primates, however, appear more sensitive to the neurotoxic effects of Mn, including disturbances of behavior and motor function (30, 32, 103, 104) . Some speculation has suggested that the difference in neurobehavioral sensitivity of rodents and primates may be related to the fact that, unlike primates, rodents do not have pigmented substantia nigra, which is a brain region of relatively high Mn uptake. However, it appears that other nuclei of the basal ganglia are more likely to be target sites of Mn neurotoxicity (29 For improvement of the exposure assessment, the U.S. EPA has recommended obtaining personal exposure measurements using a probabilistic sampling design in areas where MMT is used in gasoline (96) . At the time this recommendation was made, Canada was the only country where MMT was used in unleaded gasoline, and thus it was presumed that such studies would have to be conducted in Canada. However it was recognized that differences between U.S. and Canadian cities, including meteorology, traffic density, and the concentration of MMT in gasoline, would need to be taken into consideration in the design and interpretation of the studies. A stratified sampling design with particular emphasis on representation of the upper tail of the exposure distribution (e.g., through oversampling of high-exposure subgroups) was recommended. The U.S. EPA also proposed that personal exposure monitoring and ambient monitoring (preferably adjacent to each subject's residence) be conducted concurrently. Given seasonal differences in exposures, sampling during at least two different times or seasons of the year was advocated. As in the case of the health studies, it was intended that the Ethyl Corporation would take responsibility for developing detailed protocols for such exposure studies, subject to U.S. EPA approval.
Although the U.S. EPA and the Ethyl Corporation have been in communication on these proposals since 1991, the U.S. EPA has not yet formally notified Ethyl of the proposed testing requirements. Nevertheless the Ethyl Corporation funded a significant personal exposure study in Toronto, Canada, in 1995, the full results of which have not yet been made available to the U.S. EPA. Also, preliminary animal studies of Mn toxicity have been initiated by Ethyl (74) .
The Ethyl Corporation has also indicated an intention to conduct pharmacokinetic studies of Mn by oral and inhalation routes in rodents as well as primates. In 1991 the U.S. EPA included a recommendation to characterize the bioaccumulation of inhaled Mn, primarily to support extrapolation from less-than-lifetime, highlevel exposures to lifetime, low-level exposures. Although a bioaccumulation study would be especially valuable in the design and interpretation of a less-than-lifetime primate study, the U.S. EPA assigned a low priority to route-to-route pharmacokinetic studies because it was felt that such an extrapolation could introduce additional uncertainty in the derivation of an RfC. However, appropriate pharmacokinetic studies could provide useful dosimetric data for designing and interpreting toxicity studies. Such studies would need to investigate Mn disposition in blood, excreta, and target tissues such as brain regions, lung, reproductive organs, liver, and kidney. These studies should also examine Mn disposition in relation to gender and lifestage, from prenatal to senescence, and consider different oxidation states of Mn, particularly the divalent and trivalent forms.
Until the U.S. EPA formally notifies the Ethyl Corporation of the studies to be conducted under the authority of CAA Section 21 1 (b), any of the above proposals is subject to change. Even then, as provided in the F/FA rule (7), the Ethyl Corporation as well as the public will be afforded an opportunity to comment on the required studies proposed by the U.S. EPA, after which the U.S. EPA may modify requirements before making them final.
Although the proposed requirements are more extensive than the standard assays required under the F/FA rule, they are designed only to address specific issues directly relevant to the risk assessment of Mn in relation to MMT. In this respect some observers might prefer to characterize the prescribed studies as testing rather than research, the latter term perhaps implying a less prescriptive specification of objectives or methods. In any event it is expected that the study protocols will undergo solicited peer review to ensure that the studies will be optimally designed to address key risk assessment questions and issues. This is not to say that studies prescribed by the U.S. EPA are the only studies that could provide information of relevance to assessing the potential health risks related to MMT. A better understanding of the basic mechanisms of Mn toxicity could be quite helpful in interpreting the results of testing studies. New questions frequently arise even as testing is conducted, and independent investigations outside the focused program of studies to be prescribed by the U.S. EPA could prove valuable.
Conclusions
The importance of empirical, quantitative data on exposure and health effects for assessing risk is evident in the case of MMT. Neither assurances of benign or no detectable effects nor prophesies of impending catastrophic impacts can be given much credibility without substantially more information than has been available to date. Because MMT is already in use, the need for timely and well focused studies to better characterize the exposures and health effects resulting from this fuel additive is all the more important.
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